The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

H. Roger Lijnen

Center for Molecular and Vascular Biology

University of Leuven

Belgium

[email]@med.kuleuven.ac.be

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Center for Molecular and Vascular Biology, University of Leuven, Belgium. 1996 - 2005
  • University of Leuven, Center for Molecular/Vascular Biology, Campus Gasthuisberg, O and N Herestraat 49, Belgium. 2001
  • Center for Molecular and Vascular Biology and Laboratory for Pharmaceutical Biology and Phytopharmacology, University of Leuven, B-3000 Leuven, Belgium. 2000

References

  1. Pleiotropic functions of plasminogen activator inhibitor-1. Lijnen, H.R. J. Thromb. Haemost. (2005) [Pubmed]
  2. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Lijnen, H.R. Thromb. Haemost. (2005) [Pubmed]
  3. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. Lijnen, H.R., Alessi, M.C., Van Hoef, B., Collen, D., Juhan-Vague, I. J. Thromb. Haemost. (2005) [Pubmed]
  4. Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). Lijnen, H.R., Van Hoef, B., Umans, K., Collen, D. J. Thromb. Haemost. (2004) [Pubmed]
  5. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Lijnen, H.R., Maquoi, E., Morange, P., Voros, G., Van Hoef, B., Kopp, F., Collen, D., Juhan-Vague, I., Alessi, M.C. Arterioscler. Thromb. Vasc. Biol. (2003) [Pubmed]
  6. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Lijnen, H.R., Demeulemeester, D., Van Hoef, B., Collen, D., Maquoi, E. Thromb. Haemost. (2003) [Pubmed]
  7. Metalloproteinases in development and progression of vascular disease. Lijnen, H.R. Pathophysiol. Haemost. Thromb. (2003) [Pubmed]
  8. Matrix metalloproteinases and cellular fibrinolytic activity. Lijnen, H.R. Biochemistry Mosc. (2002) [Pubmed]
  9. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Lijnen, H.R., Maquoi, E., Hansen, L.B., Van Hoef, B., Frederix, L., Collen, D. Arterioscler. Thromb. Vasc. Biol. (2002) [Pubmed]
  10. Extracellular proteolysis in the development and progression of atherosclerosis. Lijnen, H.R. Biochem. Soc. Trans. (2002) [Pubmed]
  11. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Lijnen, H.R., Maquoi, E., Demeulemeester, D., Van Hoef, B., Collen, D. Thromb. Haemost. (2002) [Pubmed]
  12. Gene targeting in hemostasis. Alpha2-antiplasmin. Lijnen, H.R. Front. Biosci. (2001) [Pubmed]
  13. Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples. Lijnen, H.R., Bloemmen, F., Vereecken, A., Collen, D. Thromb. Res. (2001) [Pubmed]
  14. Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1. Lijnen, H.R., Van Hoef, B., Collen, D. Biochim. Biophys. Acta (2001) [Pubmed]
  15. Adipose tissue expression of gelatinases in mouse models of obesity. Lijnen, H.R., Maquoi, E., Holvoet, P., Mertens, A., Lupu, F., Morange, P., Alessi, M.C., Juhan-Vague, I. Thromb. Haemost. (2001) [Pubmed]
  16. Elements of the fibrinolytic system. Lijnen, H.R. Ann. N. Y. Acad. Sci. (2001) [Pubmed]
  17. Plasmin and matrix metalloproteinases in vascular remodeling. Lijnen, H.R. Thromb. Haemost. (2001) [Pubmed]
  18. Efegatran. Institute for drug research/IVAX. Lijnen, H.R. IDrugs (2001) [Pubmed]
  19. Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp. Lijnen, H.R., Van Hoef, B., Ugwu, F., Collen, D., Roelants, I. Biochemistry (2000) [Pubmed]
  20. Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury. Lijnen, H.R., Van Hoef, B., Dewerchin, M., Collen, D. Arterioscler. Thromb. Vasc. Biol. (2000) [Pubmed]
  21. CD9 gene deficiency does not affect smooth muscle cell migration and neointima formation after vascular injury in mice. Lijnen, H.R., Lupu, F., Collen, D., Le Naour, F., Boucheix, C. Thromb. Haemost. (2000) [Pubmed]
  22. Molecular basis of thrombolytic therapy. Lijnen, H.R., Collen, D. J. Nucl. Cardiol (2000) [Pubmed]
  23. Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). Lijnen, H.R., Arza, B., Van Hoef, B., Collen, D., Declerck, P.J. J. Biol. Chem. (2000) [Pubmed]
  24. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Lijnen, H.R., Lupu, F., Moons, L., Carmeliet, P., Goulding, D., Collen, D. Thromb. Haemost. (1999) [Pubmed]
  25. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Lijnen, H.R., Soloway, P., Collen, D. Circ. Res. (1999) [Pubmed]
  26. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Lijnen, H.R., Van Hoef, B., Vanlinthout, I., Verstreken, M., Rio, M.C., Collen, D. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  27. Matrix metalloproteinase system deficiencies and matrix degradation. Lijnen, H.R., Collen, D. Thromb. Haemost. (1999) [Pubmed]
  28. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Lijnen, H.R., Ugwu, F., Bini, A., Collen, D. Biochemistry (1998) [Pubmed]
  29. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Lijnen, H.R., Silence, J., Lemmens, G., Frederix, L., Collen, D. Thromb. Haemost. (1998) [Pubmed]
  30. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Lijnen, H.R., Van Hoef, B., Lupu, F., Moons, L., Carmeliet, P., Collen, D. Arterioscler. Thromb. Vasc. Biol. (1998) [Pubmed]
  31. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Lijnen, H.R., Wagner, E.F., Collen, D. Thromb. Haemost. (1997) [Pubmed]
  32. Characterization of the murine plasminogen/urokinase-type plasminogen-activator system. Lijnen, H.R., Van Hoef, B., Collen, D. Eur. J. Biochem. (1996) [Pubmed]
 
WikiGenes - Universities